Overview
Unlocking the Therapeutic Potential of Amylin-Based Therapies for Obesity
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start Activity
Obesity is a chronic, progressive, and relapsing disease that imposes a substantial clinical burden. Despite the availability of approved pharmacologic agents with varying mechanisms of action, efficacy, tolerability, and accessibility, only a small percentage of eligible patients are prescribed evidence-based medications, often due to clinician knowledge gaps, concerns regarding long-term safety, and a persistent but inaccurate perception of obesity as a failure of willpower rather than a multifactorial neuroendocrine disorder. Clinicians also encounter significant limitations with available therapies, including suboptimal weight loss efficacy, heterogeneous patient responses, and the difficulty of maintaining weight reduction after treatment discontinuation.
Diverse emerging neuroendocrine therapies targeting multiple metabolic pathways, such as amylin, are under investigation for obesity management. Clinicians require enhanced understanding of the complex physiology, central and peripheral mechanisms, and evolving clinical evidence supporting amylin-based therapies to counsel patients and integrate these emerging strategies into future obesity treatment approaches.
In this interactive playbook, clinicians can navigate neuroendocrine physiology, mechanisms of action, and latest clinical evidence on amylin-based therapies for obesity. Expert perspectives help put the data into context and frame future care paradigms.
Diverse emerging neuroendocrine therapies targeting multiple metabolic pathways, such as amylin, are under investigation for obesity management. Clinicians require enhanced understanding of the complex physiology, central and peripheral mechanisms, and evolving clinical evidence supporting amylin-based therapies to counsel patients and integrate these emerging strategies into future obesity treatment approaches.
In this interactive playbook, clinicians can navigate neuroendocrine physiology, mechanisms of action, and latest clinical evidence on amylin-based therapies for obesity. Expert perspectives help put the data into context and frame future care paradigms.
This educational activity is designed for endocrinologists, endocrinology NPs/PAs, obesity specialists and/or primary care clinicians
Upon completion of this activity, learners will be able to:
• Describe the physiological roles of amylin in obesity regulation
• Outline the mechanisms of action of amylin-based therapies and their clinical potential in addressing unmet needs in obesity management
• Analyze the latest clinical data on emerging amylin-based therapies for patients with obesity
• Describe the physiological roles of amylin in obesity regulation
• Outline the mechanisms of action of amylin-based therapies and their clinical potential in addressing unmet needs in obesity management
• Analyze the latest clinical data on emerging amylin-based therapies for patients with obesity
Provided by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Novo Nordisk.
Domenica M. Rubino, MD
Director, Washington Center for Weight Management and Research
Arlington, VA
Director, Washington Center for Weight Management and Research
Arlington, VA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Domenica M. Rubino, MD
Consulting/Advisor Agreements: AbbVie, AstraZeneca, Boehringer Ingelheim, Cytoki, Ferring, Lilly, Neurocrine, Novo Nordisk, Pfizer, Regeneron, Roche, Shionogi, Tern, and Zealand PharmaClinical Investigator: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Lilly, Novo Nordisk and Pfizer
The following financial relationships have been provided:
Domenica M. Rubino, MD
Consulting/Advisor Agreements: AbbVie, AstraZeneca, Boehringer Ingelheim, Cytoki, Ferring, Lilly, Neurocrine, Novo Nordisk, Pfizer, Regeneron, Roche, Shionogi, Tern, and Zealand PharmaClinical Investigator: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Lilly, Novo Nordisk and Pfizer
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use[KC2.1][NM2.2]: cagrilintide, cagrilintide–semaglutide, amycretin, eloralintide, petrelintide, AZD6234, GUBamy/ABBV-295, Met-233
To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
